Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a ...

Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

Explore how nutrition plays a crucial role in cancer prevention, treatment, and recovery, emphasizing the power of a balanced diet.

Researchers at the University of Houston are pushing the boundaries of biomedical innovation with a discovery that could transform treatment for one of cancer's most devastating complications. In a ...

Visugromab combined with nivolumab showed a median duration of response exceeding 2 years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...

A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients. It demonstrated a weight gain in patients who took the drug versus a ...

Cancer cachexia is a highly debilitating clinical syndrome of involuntary body mass loss featuring profound muscle wasting and leading to high mortality. Notably, cardiac wasting is prominent in ...